Register Now: Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development
Commentary|Videos|November 26, 2024

Complexities with Managing the Overabundance of Clinical Technology

In this video interview, Jeff Sidell, PhD, chief technology officer, Advarra, discusses how sites are being burdened by increasingly complex technologies.

In a recent video interview with Applied Clinical Trials, Jeff Sidell, PhD, chief technology officer, Advarra, discussed current challenges in clinical research technology. He highlighted the overabundance of systems and emphasized the need for integration to streamline processes and reduce administrative overhead. Sidell also discussed the potential of AI, particularly predictive analytics, to automate repetitive tasks, enhancing efficiency and quality.

A transcript of Sidell’s conversation with ACT can be found below.

ACT: What are some current trends and challenges you’re seeing right now with technology in clinical research?

Sidell: I think for the most part, it's an overabundance of technology. If you ask somebody who's working in a clinical trial at a site, how many systems they have to touch during the conduct of a clinical trial, it keeps rising over the years. I think it's now up to 20 or so. I mean, 20 separate systems that they've got to go and log into, enter data, or move data from one place to another. Not only are the systems becoming more complicated, the trials themselves are becoming more complicated, so they're going on for longer, the conduct of the trial is much more complex, so you put those two things together, and they're drowning in activities, none of which are actually administering care to a subject. It's all just overhead.


Related to this article

Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Where AI Governance in Clinical Development Falls Short
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, identifies three recurring failure modes in AI governance frameworks—and explains why responsible AI must be an ongoing operating discipline, not a one-time approval gate.
© photon_photo - © photon_photo - stock.adobe.com
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.